In vitro toxicity in long-term cell culture of MR contrast agents targeted to cartilage evaluation  by Midura, S. et al.
Osteoarthritis and Cartilage 22 (2014) 1337e1345In vitro toxicity in long-term cell culture of MR contrast agents
targeted to cartilage evaluation
S. Midura y, E. Schneider z x, F.A. Sakamoto z, G.M. Rosen x k, C.S. Winalski y z *,
R.J. Midura y
y Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
z Imaging Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
x NitroSci Pharmaceuticals, LLC, New Berlin, WI 53151, USA
k Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USAa r t i c l e i n f o
Article history:
Received 10 February 2014
Accepted 10 July 2014
Keywords:
Cartilage
Magnetic resonance imaging
Dendrimer
Contrast agent
Cytotoxicity
Chondrocyte* Address correspondence and reprint requests to:
tute, A21, Cleveland Clinic, 9500 Euclid Avenue, Cleve
216-445-3401; Fax: 1-216-445-9445.
E-mail address: winalsc@ccf.org (C.S. Winalski).
http://dx.doi.org/10.1016/j.joca.2014.07.010
1063-4584/© 2014 Osteoarthritis Research Society Ins u m m a r y
Objective: Contrast-enhanced magnetic resonance (MR) imaging methods have been proposed for non-
invasive evaluation of osteoarthritis (OA). We measured cell toxicities of cartilage-targeted low-gener-
ation dendrimer-linked nitroxide MR contrast agents and gadopentetate dimeglumine (Gd-DTPA) on
cultured chondrocytes.
Design: A long-term Swarm rat chondrosarcoma chondrocyte-like cell line was exposed for 48-h to
different salts (citrate, maleate, tartrate) and concentrations of generation one or two diaminobutyl-
linked nitroxides (DAB4-DLN or DAB8-DLN), Gd-DTPA, or staurosporine (positive control). Impact on
microscopic cell appearance, MTT spectrophotometric assays of metabolic activity, and quantitative
PicoGreen assays of DNA content (cell proliferation) were measured and compared to untreated cultures.
Results: Chondrocyte cultures treated with up to 7.5 mM Gd-DTPA for 48-h had no statistical differences
in DNA content or MTT reaction compared to untreated cultures. At all doses, DAB4-DLN citrate treated
cultures had results similar to untreated and Gd-DTPA-treated cultures. At doses >1 mM, DAB4-DLN
citrate treated cultures showed statistically greater DNA and MTT reaction than maleate and tartrate
DAB4-DLN salts. Cultures exposed to 5 mM or 7.5 mM DAB8-DLN citrate exhibited rounded cells, poor
cell proliferation, and barely detectable MTT reaction. Treatment with 0.1 mM staurosporine caused
chondrocyte death.
Conclusion: Long-term exposure, greater than clinically expected, to either DAB4-DLN citrate or Gd-DTPA
had no detectable toxicity with results equivalent to untreated cultures. DAB4-DLN citrate was more
biocompatible than either the maleate or tartrate salts. Cells exposed for 48-h to 5 mM or 7.5 mM DAB8-
DLN salts demonstrated signiﬁcant cell toxicity. Further evaluation of DAB8-DLN with clinically appro-
priate exposure times is required to determine the maximum useful concentration.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common and costly joint disease
worldwide1e3 characterized clinically by pain and loss of joint
function and structurally by progressive loss of articular cartilage
and changes in the underlying bone2,4e7. Because articular cartilage
has a poor capacity for repair, early cartilage damage diagnosis and
intervention, while changes are still minor, is critical to prevent orC.S. Winalski, Imaging Insti-
land, OH 44195, USA. Tel: 1-
ternational. Published by Elsevier Ldelay progression to clinical OA. Magnetic resonance imaging (MRI)
has proved helpful in assessing articular cartilage with both
morphological and compositional techniques4,5,8e22, however,
signal-to-noise and spatial resolution limit the sensitivity to early
cartilage degradation and determination of lesion depth, especially
with morphological imaging10,11,18e22.
The extracellular matrix of cartilage is paramount to its
biomechanical function and is composed of collagen and glycos-
aminoglycans (GAG), primarily as glycoconjugates in the form of
aggrecan. A hallmark of cartilage degeneration is reﬂected by al-
terations in the negatively-charged GAG. Early this may be an up-
regulation or down-regulation, however as the disease progresses
GAG is lost, resulting in lower ﬁxed charge density (FCD) and loss oftd. All rights reserved.
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directly with sodium (Naþ) imaging or indirectly using positively-
or negatively-charged contrast agents that distribute within carti-
lage relative to the FCD23e25. Unfortunately, currently available FCD
imaging techniques (Naþ MRI; delayed gadolinium enhanced MRI
of cartilage [dGEMRIC]) are not optimal. Naþ MRI is inherently
difﬁcult with low spatial resolution and requirement of additional
hardware and software, including high ﬁeld strength (>3 T) MR
systems20,24,25. dGEMRIC exploits the 2 charge on gadopentetate
dimeglumine (Gd-DTPA) to measure FCD. However, with dGEMRIC,
the cartilage enhancement is not visually obvious with typical MR
acquisitions, hence T1 maps must be calculated from multiple MRI
acquisitions followed by off-line processing15e17,20,26,27. In addition,
Gd-DTPA has been associated with nephrogenic systemic ﬁbrosis
(NSF) in patients with renal insufﬁciency presumably because the
heavy metal dissociates from its chelate28e31. Additionally, an
in vitro study demonstrated Gd-DTPA toxicity in bovine chon-
drocytes with induction of apoptosis and an increase in proteo-
glycan production32.
Dendrimers to which ﬁve-membered ring nitroxides are cova-
lently attached (dendrimer-linked nitroxide, DLN), have been pro-
posed as MRI contrast agents for cartilage imaging33,34. DLN MRI
contrast agents do not carry the risk of heavy metal ion toxicity and
were designed to be positively-charged at physiologic pH with
preferential distribution to areas with higher GAG concentrations.
Therefore, healthy cartilage has a higher uptake of the contrast
agent33,34 resulting in brighter signal on clinical MR images and
potentially enabling early identiﬁcation of cartilage degeneration
without the need of T1 maps.
To date, the toxicity of DLNs on chondrocytes has not been
evaluated. Herein, we study the effect of long-term exposure of
cultured chondrocytes to diaminobutyl-linked nitroxides, genera-
tion one DAB4-DLN [Fig. 1(A)] and generation two DAB8-DLN
[Fig. 1(B)], in comparison to Gd-DTPA, staurosporine (positive
control) and untreated cell cultures (negative control). The effect of
48-h exposure on cell proliferation, intracellular metabolism, and
microscopic cell appearance were compared for different concen-
trations and for different salts of the DLN contrast agents using a
chondrocyte-like cell line derived from the Swarm rat chon-
drosarcoma (LTC-RCS)35.Fig. 1. Chemical structures of DAB-DLN contrast agents. DAB4-DLN (A) has four terminal
(indicated by “þ” signs) at physiologic pH while DAB8-DLN (B) has eight terminal nitroxidMaterial and methods
Materials
All reagents used were of highest purity. Cell culture materials
included: 10 Trypsin (Gibco-Invitrogen, Grand Island, NY USA), L-
Glutamine (Sigma-Aldrich, St. Louis, MO USA), Dulbecco's modiﬁed
Eagle's mediumwith low glucose (DMEM; Sigma-Aldrich, St. Louis,
MO USA), Penicillin (Sigma-Aldrich, St. Louis, MO USA), and
Streptomycin (Gibco-Invitrogen, Grand Island, NY USA); Hank's
Balanced Salt Solution without Calcium or Magnesium (Mediatech,
Herndon, VA USA); fetal bovine serum (FBS, Atlanta Biologicals,
Atlanta, GA USA); T-75 tissue culture ﬂasks, 96-well and 48-well
plates (BD Falcon, Franklin Lakes, NJ USA).Chondrocyte-cell line
An established long-term culture chondrocyte-like cell line
(LTC-RCS) derived from the Swarm rat chondrosarcoma cell
line35,36 was obtained from Dr Veronique Lefebvre (Cleveland
Clinic, Cleveland, OH USA) with permission from Dr James Kimura
(Henry Ford Hospital, Detroit, MI USA). LTC-RCS chondrocytes were
selected because they stably maintain a chondrocytic phenotype
under monolayer culture conditions which permits conventional
microscopic imaging evaluation37. LTC-RCS chondrocytes were
cultured in a T75 culture ﬂask using 30 ml of DMEM containing
50 units/ml penicillin and streptomycin and 10% FBS; in a humid-
iﬁed atmosphere of 5% CO2 at 37C. The cells were passaged every
4e5 days after reaching approximately 70% conﬂuency
(~1.4  105 cells/cm2). For all experiments, LTC-RCS chondrocytes
were seeded at 180 cells/mm2.Photomicrographs
Phase contrast photomicrographs were taken with an Olympus
CKX 41 inverted microscope with an attached DP21 digital camera
(Olympus America, Melville, NY USA). Bright ﬁeld photomicro-
graphs were taken of 96-well cultures following incubation with
MTT reagent (details below). For morphological documentation,ﬁve-membered nitroxide groups and two tertiary amines that are positively charged
e groups and six tertiary amines.
S. Midura et al. / Osteoarthritis and Cartilage 22 (2014) 1337e1345 1339phase contrast photomicrographs were taken of 48-well plate
cultures seeded and treated under identical conditions.
DLN syntheses
Synthesis of DAB4-DLN (DAB-dendr-(3-amido-2,2,5,5-
tetramethyl-1-pyrrolidinyl-1-oxyl)4) and DAB8-DLN (DAB-dendr-
(3-amido-2,2,5,5-tetramethyl-1-pyrrolidinyl-1-oxyl)8) followed
literature methods33,38 with minor modiﬁcations as described in
the Supplemental Materials. The compounds were isolated by ﬂash
column chromatography and purity tested by thin layer chroma-
tography (TLC) and mass spectrometry. The citrate, maleate and
tartrate salts of DLNs were then prepared as described in
Supplemental Materials. For example, to synthesize the citrate
salts, DAB4-DLN or DAB8-DLN was dissolved in dry CHCl3. This
solution was mixed with anhydrous citric acid (Sigma-Aldrich
Chemical Co., St. Louis, MO USA) dissolved in absolute ethanol at an
equal mole ratio and subsequently evaporated to dryness, using a
rotary evaporator. The salt was then dried under high vacuum until
yellow crystals were free of solvents.
Test solutions
All DLN stock solutions were dissolved in growth medium to
20 mM, diluted in the appropriate volume of fresh growth media to
achieve working concentrations, and ﬁlter-sterilized through a
0.22-micron Millex GV PVDF Syringe Driven Filter Unit (Millipore,
Bedford, MA USA). The pH for each DLN stock solution ranged from
6.8 to 7.2 assuring that the pH of the culture medium was not
altered at the desired ﬁnal concentration. Gd-DTPAwas obtained as
a commercial sterile stock solution at 500 mM (Magnevist, Bayer
Healthcare Pharmaceuticals, Germany). Dilutions of all stock solu-
tions were prepared using complete growth medium with ﬁnal
concentrations of 1.0, 5.0 and 7.5 mM above the cells. The medium
in each well was replaced with an equal volume of the designated
treatment at the appropriate dose, and incubated for an additional
48-h.
Controls
Untreated cells served as negative controls. Staurosporine
(Calbiochem #3970743-1, San Diego, CA USA), which can induce
apoptosis, was used as the cytotoxic positive control at concen-
trations of 0.01, 0.1, 0.5, 1, 5 and 10 mM.
DNA measurement
The Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen P7589,
Eugene, OR USA) was used to quantify cell proliferation. LTC-RCS
cells were seeded at 180 cells per mm2 and incubated for 24-h, at
this time some cultures were processed for DNAmeasurement (24-
h baseline). Remaining cultures had medium exchanges without
(untreated/negative control) or with 1 mM, 5 mM, or 7.5 mM
concentrations of test reagent and incubated for an additional 48-h.
After 48-h of treatment (72-h post-seeding), the media was
removed from all cultures and the cell layers processed for DNA
measurement per the manufacturer's directions. Assays were read
in a SpectraMaxM2 ﬂuorometer (Molecular Devices, Sunnyvale, CA
USA; SoftMax Pro 5.4.1 software). DNA values, calculated in ng per
culture, were assessed using a dsDNA standard curve.
MTT assay
To assess the overall metabolic effects of the various DLNs and
Gd-DTPA, an MTT colorimetric assay (ATCC (30e101 K), Manassas,VA USA) was performed on cells after 48-h of treatment. This assay
measures conversion of tetrazolium MTT (3-(4,5-dimehylthiazolyl-
2)2,5-diphenyltetrazolium bromide) to formazan via oxidative
respiration within mitochondria and is a direct measure of a cell's
metabolic activity39. At 24-h baseline growth medium was
exchanged and the cultures were returned to the incubator for an
additional 48-h with or without various treatments. After 48-h (72-
h post-seeding), the cultures were processed for MTT conversion to
formazan per the manufacturer's directions. Bright ﬁeld photomi-
crographs were taken prior to formazan solubilization. A formazan
standard curve (MTT Formazan (M2003) Sigma, St. Louis, MO USA)
was included in each experiment. The concentration of formazan
was normalized to DNA content within the same experiment to
assess cellular metabolic activity.
Statistical analysis
There were 2e3 trials per measurement; each trial had triplicate
wells that were independently analyzed. This resulted in nine
cultures for Gd-DTPA, DAB4-DLN citrate and DAB8-DLN citrate, and
three cultures for DAB4-DLN maleate and DAB4-DLN tartrate
treated groups. The data were compared in an automated,
sequential leave-one-out manner, using a one-way analysis of
variance (ANOVA) with a post-hoc Tukey Test using Origin 7.5
(OriginLab, Northampton, MAUSA); signiﬁcancewas set at P< 0.05.
The Tukey Test results in a yes/no response to the hypothesis (e.g.,
are there signiﬁcant differences between the wells with P < 0.05).
Results
Successful synthesis of the 3 DAB4-DLN salts (citrate, maleate
and tartrate) and 3 DAB8-DLN salts (citrate, maleate and tartrate)
was conﬁrmed by mass spectrometry and lack of impurities
demonstrated by TLC and mass spectroscopy.
Effect of DLN citrates, Gd-DTPA or staurosporine on chondrocyte
culture appearance
At 24-h, all cultures appeared subconﬂuent on phase contrast
photomicrographs with roughly half of all cells appearing fully
spread and adherent (Fig. 2, arrowhead) while the remainder
appeared as refractile doublet-cells suggestive of mitosis (Fig. 2,
arrow). This was the treatment baseline, i.e., 24-h after cell-seeding,
prior to the exchange with fresh growth medium containing the
designated agents. Results of the 24-h treatment (48-h post-
seeding) and 48-h treatment (72-h post-seeding) photomicro-
graphs are discussed below (see timeline, Fig. 2).
After 24-h treatment, untreated negative control, 7.5 mM Gd-
DTPA and 7.5 mM DAB4-DLN citrate treated cultures showed
increased adherent cell numbers and a few refractile doublet-cells
per ﬁeld. Cells treated with lower concentrations of these com-
pounds and the 1 mM DAB8-DLN citrate (not shown) appeared
identical to the negative control. The 5 mM DAB8-DLN citrate cul-
tures (not shown) demonstrated no cellular increase over 24-h, but
all cells were still adherent and well-spread. At this same time-
point, cultures exposed to 1 mM staurosporine or 7.5mMDAB8-DLN
citrate showed no increase in cell numbers per ﬁeld and nearly all
cells were rounded (Fig. 2).
After 48-h treatment, untreated control, 7.5 mM Gd-DTPA and
7.5 mM DAB4-DLN citrate treated cultures showed continued in-
creases in adherent cell numbers per ﬁeld while cultures exposed
to 1 mM staurosporine or 7.5 mM DAB8-DLN citrate did not change
their appearance compared to 24-h treatment. However, the
presence of smaller rounded bodies and debris in the staurosporine
treated cultures were suggestive of some cell death (Fig. 2, white
Table I
Effect of Staurosporine on LTC-RCS chondrosarcoma cells
Sample DNA/well (ng) Formazan/well (mg) Formazan/DNA
(mg/ng)
24-h baseline 140 ± 10* 71.2 ± 10.6* 0.51 ± 0.08*
72-h control 806 ± 83 249.8 ± 37.7 0.31 ± 0.06
Staurosporine, 0.01 mM 180 ± 31* 55.7 ± 14.3* 0.30 ± 0.14
Staurosporine, 0.1 mM 15 ± 5* ND e
Staurosporine, 0.5 mM 3 ± 4* ND e
Staurosporine, 1 mM 1 ± 0.5* ND e
Staurosporine, 5 mM 0.5 ± 0.5* ND e
Staurosporine, 10 mM 1 ± 0.5* ND e
DNA assay was used to determine relative cell numbers per culture. Formazan
product from an MTT assay was used to determine relative metabolic rates per
culture. Formazan product was normalized to DNA values to determine the relative
cellular metabolic rates. Cultures were exposed to the stated concentrations of
staurosporine for a total of 48-h (from 24-h to 72-h incubation time); ND: not
detectable at the assay lower limit; values shown are mean ± 95% CI (n ¼ nine total
cultures from three independent trials); *P < 0.001 compared to 72-h control using
one-way ANOVA followed by a Tukey means comparison test.
Fig. 2. Appearance of LTC-RCS chondrocytes in culture at 24-h, 48-h and 72-h post-
seeding in the presence or absence of Gd-DTPA, DAB-DLN citrates, or staurosporine.
All photomicrographs shown are phase contrast images taken at 20 magniﬁcation.
The 100-micron scale bar provided applies to all images. A diagrammatic represen-
tation of the experimental protocol is shown at the top of the ﬁgure. All treatments
were added at the 24-h medium exchange (baseline) and continued for 48-h duration
(ending 72-h after seeding). Black arrowhead points to an example of an adherent and
spread LTC-RCS chondrocyte; black arrow points to a pair of newly divided cells that
are adherent but not yet spread out; white arrowhead points to small debris particles
apparent in the staurosporine treated samples.
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cultures.Fig. 3. DNA content of LTC-RCS chondrocyte cultures treated for 48-h in the presence
or absence of Gd-DTPA or DAB-DLN salts. All treatments were added at the 24-h
medium exchange and continued for 48-h duration (ending at 72-h after seeding).
Panel A shows a comparison of DNA content per culture well for untreated (gray line),
Gd-DTPA, DAB4-DLN citrate and DAB8-DLN citrate treated cultures. Data are
mean ± 95% CI; P values compared to untreated control are: a < 0.001, b ¼ 0.022,
c < 0.001, d < 0.001, and e < 0.001. Panel B shows a comparison of DNA content per
culture well for untreated (gray line), DAB4-DLN maleate, DAB4-DLN citrate and DAB4-
DLN tartrate treated cultures. Data are mean ± 95%CI; P values compared to untreated
control are: a < 0.001, b ¼ 0.022, c < 0.001, d < 0.001, e ¼ 0.001, f < 0.001, and g < 0.001.Effects of DLN citrates, Gd-DTPA or staurosporine on the DNA
content of chondrocyte cultures
The DNA content of untreated control LTC-RCS chondrocyte
cultures increased over 5-fold between the 24-h baseline and 72-h
of incubation (Table I). By contrast, 48-h incubation with 1 mM
staurosporine resulted in a total loss of their baseline DNA content
(Table I) despite the continued presence, on phase contrast mi-
croscopy, of rounded structures, that were likely remnants of dead
cells and extracellular matrix (Fig. 2).
Chondrocyte cultures treated with Gd-DTPA at 1 mMe5 mM
concentrations for 48-h did not appreciably differ in DNA content
from untreated controls [Fig. 3(A)]. Cultures exposed to 7.5 mMGd-
DTPA contained 88% of the DNA content of untreated controls and
this value approached statistical signiﬁcance (P ¼ 0.067) [Fig. 3(A)].
Cultures treated 48-h with 1 mM DAB4-DLN citrate did not have
statistically different DNA levels from the untreated controls
[Fig. 3(A)]. Cultures treated over the same incubation period with
5 mM or 7.5 mM DAB4-DLN citrate contained signiﬁcantly lowerDNA contents measuring 83% (P < 0.001) or 77% (P ¼ 0.023),
respectively, of untreated controls [Fig. 3(A)].
All cultures treated 48-h with DAB8-DLN citrate exhibited mean
DNA contents signiﬁcantly lower than untreated controls [Fig. 3(A),
Fig. 4. Formazan staining of LTC-RCS chondrocytes after MTT assay in the presence or
absence of Gd-DTPA, DAB-DLN citrates, or staurosporine. All photomicrographs shown
are bright ﬁeld images taken at 20magniﬁcation. The 100-micron scale bar provided
applies to all images. Images of formazan staining of untreated control cultures are
provided for both 24-h baseline and 72-h endpoint; all other images of treated cultures
are representative of the 72-h (48-h treatment) endpoint only.
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DLN citrate exhibited 81% that of untreated controls, not statisti-
cally signiﬁcantly different from higher concentrations of Gd-DTPA
or DAB4-DLN. However, cultures treated with 5 mM or 7.5 mM
DAB8-DLN citrate contained only 10% of the DNA content of un-
treated control cultures which was less than half of their baseline
values [Fig. 3(A) and Table I] indicating a loss of DNA over the 48-h
treatment.
Effects of different DLN salts on the DNA content of chondrocyte
cultures
We evaluated the effects of different salts of the two DLNs on
cell DNA content (DAB8-DLN data not shown). After a 48-h treat-
ment with 1mM, 5mM, or 7.5 mMDAB4-DLNmaleate, cell cultures
contained statistically signiﬁcantly less DNA than untreated control
cultures with levels measuring 75% (P ¼ 0.001), 63% (P < 0.001), or
58% (P < 0.001) of the control, respectively [Fig. 3(B)]. A 48-h
treatment with 1 mM, 5 mM, or 7.5 mM DAB4-DLN tartrate resul-
ted in DNA contents of 95% (P ¼ 0.26), 71% (P < 0.001), or 58%
(P < 0.001), respectively, of untreated controls [Fig. 3(B)]. Overall,
cultures treated with the DAB4-DLN citrate salt contained a higher
DNA content than those treated with maleate or tartrate DAB4-DLN
salts for all concentrations.
Effect of DLN citrates, Gd-DTPA or staurosporine on metabolic
activity of chondrocytes
The MTT assay was used to determine the overall metabolic
activities of LTC-RCS chondrocytes in the presence of DLN salts, Gd-
DTPA or staurosporine for 48-h treatment by determining the de-
gree of formazan staining. Immediately after performing the MTT
assay, pictures taken of untreated controls at 24-h baseline and 72-
h post-seeding showed adherent cells with intracellular formazan
salt deposits (Fig. 4) and an increase in cell numbers over this 48-h
treatment.
At all tested doses, 48-h treatment with staurosporine LTC-RCS
cultures exhibited minimal, irregular formazan staining patterns
and no increase in cell numbers (Fig. 4). In particular, treatment of
chondrocytes with 1 mM staurosporine greatly suppressed for-
mazan production, an indication of poor mitochondrial respiration
in all cells. In contrast, Gd-DTPA or DAB4-DLN citrate treated cells at
all doses yielded similar formazan staining patterns as untreated
controls (Fig. 4).
Cultures treated with the lowest dose of DAB8-DLN citrate
(1 mM) exhibited formazan staining patterns and cell numbers per
ﬁeld comparable to untreated control (Fig. 4). However, cells
treated with 5 mM or 7.5 mM DAB8-DLN citrate concentrations
exhibited reductions in formazan staining levels and fewer cells per
ﬁeld compared to untreated control.
Quantitative analysis of formazan production showed untreated
cultures had a 3.5-fold increase in formazan product per well be-
tween 24-h and 72-h, whereas those treated with 0.01 mM staur-
osporine resulted in a formazan content that was around 20% lower
than baseline (Table I). Formazan production for cultures treated
with staurosporine at higher doses was below the lower limit of the
MTT assay (Table I).
At all doses, cultures treated with Gd-DTPA or DAB4-DLN citrate
for 48-h did not signiﬁcantly differ in formazan content from un-
treated controls [Fig. 5(A)]. Cultures treated for 48-h with 1 mM,
5 mM or 7.5 mM DAB8-DLN citrate exhibited statistically signiﬁ-
cantly lower formazan contents 75% (P ¼ 0.001), 10% (P < 0.001), or
10% (P < 0.001) of untreated control, respectively [Fig. 5(A)].
To evaluate themetabolic activity of individual cells, the amount
of formazan produced was normalized by the amount of DNAwithin the same experiment. Forty-eight hour treatment with
1 mM, 5 mM or 7.5 mM Gd-DTPA [Fig. 6(A)] did not appreciably
alter the amount of formazan per ng DNA compared to that of
control chondrocytes. Treatment with 1 mM DAB4-DLN citrate did
not exhibit statistically different amounts of formazan per ng DNA
compared to untreated control cells [Fig. 6(A), P ¼ 0.31]. However,
cultures treated with 5 mM or 7.5 mM DAB4-DLN citrate, demon-
strated statistically signiﬁcant 129% (P ¼ 0.041) or 139% (P ¼ 0.001)
greater in formazan per ng DNA, respectively, over untreated con-
trols. These data suggest the LTC-RCS chondrocytes are metaboli-
cally responding to these doses of DAB4-DLN citrate with enhanced
mitochondrial activity.
Treatment for 48-h with 1 mM DAB8-DLN citrate yielded an
amount of formazan per ng DNA that was 86% of untreated control
(P ¼ 0.23; Fig. 6(A)). DAB8-DLN citrate treatments at 5 mM and
7.5 mM produced signiﬁcantly less formazan per ng DNA, 9%
(P < 0.001) and 0% (P < 0.001) respectively, compared to untreated
control cultures (Fig. 6A). In cultures treated for 48-h with higher
concentrations of DAB8-DLN citrate, the remaining viable cells did
not produce as much formazan per ng DNA as untreated controls
indicating a negative impact on mitochondrial activity of LTC-RCS
chondrocytes.
Effects of different DLN salts on the metabolic activity of
chondrocytes
Following 48-h treatment, cultures exposed to 1 mMDAB4-DLN
maleate [Fig. 5(B)] yielded approximately 10% less formazan
Fig. 5. Formazan product content of LTC-RCS chondrocyte cultures treated for 48-h in
the presence or absence of Gd-DTPA or DAB-DLN salts. All treatments were added at
the 24-h medium exchange and continued for 48-h duration (ending at 72-h after
seeding). Panel A shows a comparison of formazan product content per culture well
for untreated (gray line), Gd-DTPA, DAB4-DLN citrate and DAB8-DLN citrate treated
cultures. Data are mean ± 95%CI; P values compared to untreated control are:
a ¼ 0.001, b < 0.001, and c < 0.001. Panel B shows a comparison of formazan product
content per culture well for untreated (gray line), DAB4-DLN maleate, DAB4-DLN cit-
rate and DAB4-DLN tartrate treated cultures. Data are mean ± 95%CI; P values
compared to untreated control are: a ¼ 0.001, b ¼ 0.001, c < 0.001, d < 0.001, and
e < 0.001.
Fig. 6. Formazan product normalized to DNA content of LTC-RCS chondrocyte cultures
treated for 48-h in the presence or absence of Gd-DTPA or DAB-DLN salts. All treat-
ments were added at the 24-h medium exchange and continued for 48-h duration
(ending at 72-h after seeding). Panel A shows a comparison of formazan product per
DNA content for untreated (gray line), Gd-DTPA, DAB4-DLN citrate and DAB8-DLN
citrate treated cultures. Data are mean ± 95%CI; P values compared to untreated
control are: a ¼ 0.041, b ¼ 0.001, c < 0.001, d < 0.001. Panel B shows a comparison of
formazan product per DNA content for untreated (gray line), DAB4-DLN maleate, DAB4-
DLN citrate and DAB4-DLN tartrate treated cultures. Data are mean ± 95%CI; P values
compared to untreated control are: a ¼ 0.041, b ¼ 0.001, c ¼ 0.003, d ¼ 0.023, e < 0.001,
and f ¼ 0.001.
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Cultures treated for 48-h with 5 mM or 7.5 mM DAB4-DLN maleate
yielded statistically signiﬁcantly less formazan product per well
measured at only 40% of untreated control cultures (P < 0.001). The
formazan content per well for cultures treated 48-h with DAB4-
DLN tartrate [Fig. 5(B)] was statistically signiﬁcantly lower than
untreated control at all concentrations measuring between 50%
(P ¼ 0.001) and 60% (P < 0.001) of control [Fig. 5(B)]. The cultures
exposed for 48-h to DAB4-DLN citrate contained higher formazan
content per culture than those treated with identical concentra-
tions of the other salts.
Cultures treated 48-h with 1 mM DAB4-DLN maleate [Fig. 6(B)]
made as much formazan product per ng DNA as untreated controls
and those treated with 1 mM DAB4-DLN citrate. However, cultures
treated with higher concentrations, 5 mM or 7.5 mM, of DAB4-DLN
maleate made statistically signiﬁcantly less, only 56% (P < 0.001) or
61% (P ¼ 0.001) respectively, of the formazan product per ng DNA
than untreated controls. Cultures treated 48-h with 1 mM, 5 mM or
7.5 mM DAB4-DLN tartrate made 67% (P ¼ 0.003), 92% (P ¼ 0.36)
and 77% (P¼ 0.023), respectively, the formazan product per ng DNA
of untreated controls [Fig. 6(B)]. Of all the salts tested, DAB4-DLNcitrate demonstrated the least impact on mitochondrial activity of
LTC-RCS metabolism.Discussion
Toxicity is an important consideration in choosing a contrast
agent for diagnostic arthrography. We measured the toxicities of
long-term exposure of two low-generation dendrimer-linked
nitroxides, DAB4-DLN and DAB8-DLN, and a commonly used agent,
Gd-DTPA, in comparison to untreated controls and a known cyto-
toxic agent, staurosporine, in the LTC-RCS chondrocyte-cell line.
While 48-h treatment with the contrast agents exceeds the antic-
ipated clinical exposure of articular chondrocytes during arthrog-
raphy, we chose this time to ensure our assays were maximally
sensitive to low levels of toxicity.
We found little to no evidence of toxicity following 48-h expo-
sure of the chondrocyte-cell line to DAB4-DLN citrate or Gd-DPTA
at any concentration up to 7.5 mM with results of the assays of
cell metabolism equivalent to the untreated cells. Treatment with
the 5 mM and 7.5 mM concentrations of DAB4-DLN citrate showed
S. Midura et al. / Osteoarthritis and Cartilage 22 (2014) 1337e1345 1343mild diminution of cell proliferation. By comparison, DAB8-DLN
citrate showed greater toxicity at these long exposure times. Cul-
tures exposed to 1 mM DAB8-DLN citrate demonstrated signiﬁ-
cantly less DNA per well at 48-h, 81% of control, indicating less cell
proliferation. The effect of 1 mM DAB8-DLN citrate on cellular
metabolism normalized to DNA content was diminished, but not
signiﬁcantly. Toxicity of DAB8-DLN citrate was even greater at
higher concentrations showing only 10% of the DNA per well of
untreated control indicating a net loss of cells compared to base-
line. There was also a severe effect on cellular metabolism at the
higher concentrations. At all concentrations, DAB4-DLN citrate
yielded greater cell numbers and metabolic activity than either the
maleate or tartrate salts, indicating the citrate salt is more
biocompatible in chondrocyte cultures. These effects are attributed
to the compounds and their salts given the high level of purity of
the DAB4-DLN and DAB8-DLN conﬁrmed bymass spectroscopy and
TLC.
Dendrimers are branched compounds synthesized by iterative
addition of terminal groups to a molecular backbone. Each iteration
increases the “generation” of the dendrimer by one and generally
doubles the number of terminal groups. In the DAB family of den-
drimers, as with other dendrimeric compounds, cellular toxicity
and extent of DNA interactions have proved to be both concentra-
tion and generation dependent40. Malik et al.41 found
concentration-dependent cytotoxicity, hemolysis and changes in
red cell morphology depended also on the cell-type and dendrimer
generation with DAB64 (generation-5) toxicity > DAB32 (genera-
tion-4) > DAB16 (generation-3). The hemolysis results were inde-
pendently conﬁrmed42,43 in studies showing DAB64 toxicity was
greater than DAB32.
Surface modiﬁcation of higher generation dendrimers has been
found to decrease toxicity by altering the type and extent of cellular
and DNA interactions. Addition of molecules to the terminal groups
of dendrimers is believed to reduce cytotoxicity by sterically
shielding the free primary amino groups at the periphery of the
dendrimers thereby preventing their interaction with cell mem-
branes43e47. Agashe et al.43 found DAB64 conjugated with amino
acids had signiﬁcantly reduced hemolysis, with no concentration-
or time-dependent cytotoxicity compared to the unsubstituted
dendrimer. Fluorescent-labeled derivatives of DAB64 were found
by Stasko et al.44 to have signiﬁcantly reduced acute cytotoxicity in
human umbilical vein endothelial cells. Conjugation of a peptide to
DAB64 was found to signiﬁcantly reduce cytotoxicity in HIV-
infected macrophages45. Ziemba et al.46 found the degree of den-
drimer surface modiﬁcation with maltotriose correlated with the
severity of toxicity.
The majority of publications regarding toxicity have focused on
large, higher generation dendrimers like DAB64 with few in-
vestigations evaluating smaller dendrimers such as DAB4 and
DAB8. Greater toxicity has been found for higher generation den-
drimeric compounds. Kou et al.47 found hydrogen peroxide pro-
duction was strongly inﬂuenced by the dendrimer surface with U-
937 human macrophages. The dramatic and signiﬁcant changes in
macrophage cell size and complexity was greater with DAB16 than
DAB8. Treated cells had a higher sub G1 phase, indicative of
apoptosis, than did untreated cells; with ﬁndings more pronounced
for DAB16 than DAB8. Zinselmeyer et al.48 found the cytotoxicity to
be mostly generation dependent with DAB64
toxicity > DAB32 > DAB16 > DOTAP > DAB4 > DAB8 following a 4-h
incubation with a human epidermoid carcinoma cell line (A431,
ATCC CRL-1555). Of note in this study, generation-1 (DAB4) had
greater cytotoxicity than generation-2 (DAB8), with 4- and 5-fold
less toxicity, respectively, than observed for DOTAP48. Hollins
et al.49 also used the A431 cell line and found DAB16
cytotoxicity > DAB8. Tack et al.50 investigated cellular toxicity infour cell lines using DAB64, DAB32 and DAB8 with both external
surface and internal modiﬁcations. When acetyl groups were con-
jugated to terminal amines of DAB8 and formed a terminal amide,
similar to the DAB8-DLN evaluated in our investigation, lower
cellular toxicity was found with no toxicity observed following a 4-
day treatment for concentrations below 100 mM50.
Even with our small dendrimeric compounds, we found both
generational and concentration dependence for DAB-DLN cyto-
toxicity with the LTC-RCS cell line. In variance with the work by
Zinselmeyer et al.48, exposure to DAB8-DLN had a greater
negative effect on overall cellular metabolism and proliferation
than DAB4-DLN. Unexpectedly, we also found the anion chosen
for the DLN salt to be a contributor to cell toxicity, with
maleate > tartrate > citrate.
While direct evaluations are needed, the implication of this cell
toxicity study is that even excessive exposure times to 1 mMDAB8-
DLN citrate and up to 7.5 mM of DAB4-DLN citrate should prove
clinically acceptable. Therewas no signiﬁcant effect onmetabolism,
as measured by MTT assay and results were similar to the clinically
used agent Gd-DTPA. While exposure to 1 mM DAB8-DLN citrate
diminished DNA production, adult articular chondrocytes normally
exhibit little proliferation raising questions about the clinical rele-
vance of this result. Previous histological assessment of rabbit stiﬂe
joints 24-h following intra-articular injection of either saline, Gd-
DTPA, DAB16-DLN, or DAB32-DLN showed low synovial inﬂam-
matory and necrosis scores34. Minimal synovial inﬂammatory
responsewas seen in 2/4 joints injectedwith DAB16-DLN, 3/7 joints
injected with DAB32-DLN, 2/5 injected with Gd-DTPA, and 1/6
injected with saline34. While the saline group had a lower synovial
inﬂammatory score, there was no measurable difference between
the DLNs and Gd-DTPA34. The lower generation DAB4-DLN and
DAB8-DLN studied herein would be expected to have even lower
effects.
In our study, exposure to Gd-DTPA up to 7.5 mM was similar to
DAB4-DLN citrate with no statistically signiﬁcant toxicity observed.
A prior study of Gd-DTPA toxicity on cultured adult human chon-
drocytes isolated from femoral heads obtained at hemiarthroplasty
showed no signiﬁcant decrease in cell proliferation 24-h after
exposure to concentrations up to 10 mM51; 20 mM Gd-DTPA
showed a signiﬁcant decrease in cell proliferation51.
A potential limitation of our study is the much longer cell in-
cubation period than the expected residence time for DLNs in an
in vivo joint (intra-articular half-life 2.6e3.5 h for DAB16-DLN and
DAB32-DLN in rabbits)34. However, with the conservative
assumption of a 4-h intra-articular half-life and an expected clinical
dose of 5 mM, the area under the pharmacokinetic concentration
curve for arthrography is estimated at 28 mM-h implying a >12
safety margin over the 360 mM-h total exposure in our experi-
ments (48-h treatment at 7.5 mM without signiﬁcant toxicity for
DAB4-DLN or Gd-DTPA), but this must be conﬁrmed in vivo.
LTC-RCS chondrocytes were used in this study because they
maintain a highly stable chondrocytic phenotype when cultured
undermonolayer conditions35. In addition, they highly express type
II collagen and aggrecan, and do not express type I or type X
collagen, making them a relevant model system. Yet chondrocytes
in adult human cartilage are non-proliferating and their interaction
with the surrounding 3-dimensional extracellular matrix is a factor
inﬂuencing their ability to maintain a stable differentiated state.
Thus, the ﬁndings from the current study will need to be veriﬁed in
cultures of adult human chondrocytes.
In conclusion, based on these cell studies, the citrate salt of
DAB4-dendrimer linked nitroxide appears to be the least toxic and
in vivo testing prior to progression to a clinically approved MR
contrast agent is warranted. In addition, investigation of DAB8-DLN
toxicity at shorter, more relevant exposure times as well as using
S. Midura et al. / Osteoarthritis and Cartilage 22 (2014) 1337e13451344adult human articular chondrocytes may demonstrate that higher
concentrations may be clinically acceptable.
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